Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Applications include detailed scientific rationale and supporting clinical evidence
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The opening of our 1000th pharmacy in Karnataka marks an important step
The initiative is focused on a problem that continues to plague cancer outcomes in India
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Subscribe To Our Newsletter & Stay Updated